Aims We evaluated the feasibility and the acute performance of the everolimus-eluting
bioresorbable vascular scaffolds (BVS) for the treatment of patients presenting with ST …

Objectives To evaluate safety and efficacy of the everolimus-eluting bioresorbable scaffold
(BVS) in patients with ST-segment elevation myocardial infarction (STEMI). Background …

Aims: Limited data are currently available on midterm outcomes after implantation of
everolimus-eluting bioresorbable vascular scaffolds (BVS) for treatment of acute ST …

Abstract Aims Bioresorbable vascular scaffolds (BVSs) have been studied in chronic
coronary artery disease, but not in acute ST-segment elevation myocardial infarction …

Aims: Recent studies have demonstrated favourable clinical outcomes for the everolimus-
eluting bioresorbable vascular scaffold (BVS) ABSORB™ in patients with stable coronary …

Objective of this study was to assess the clinical performance of bioresorbable vascular
scaffold (BVS) compared to everolimus-eluting stent (EES) in subjects with ST-segment …

Aims: In this multicentre prospective registry we sought to evaluate the immediate and
midterm clinical outcomes following single or multiple overlapping bioresorbable vascular …

Objectives: The purpose of this study was to compare the 1-year outcome between
bioresorbable vascular scaffold (BVS) and everolimus-eluting metallic stent (EES) in ST …

Objectives: This study sought to report on clinical outcomes beyond 1 year of the BVS
Expand registry. Background: Multiple studies have proven feasibility and safety of the …

Objectives The purpose of this study was to describe the multimodal outcome 12 months
after implantation of coronary bioresorbable scaffolds (BVS) for the treatment of patients with …